Know Cancer

or
forgot password

C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment


N/A
20 Years
N/A
Open (Enrolling)
Both
Multiple Myeloma

Thank you

Trial Information

C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment


Inclusion Criteria:



- at least 20 years of age

- previously untreated

- complete pre-treatment clinical staging including bone marrow examination

- written informed consent to participate in the study

Exclusion Criteria:

- concurrent active malignant tumor(s)

- pregnant or breast feeding women

- non-compliant to PET/CT or to MRI

- marked renal impairment (contraindicated for contrast-enhanced MRI)

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic

Outcome Measure:

Pretreatment lesion detection

Outcome Description:

Reference standards: bone marrow examination and whole-body dynamic contrast-enhanced MRI

Outcome Time Frame:

Within 2 weeks before initiation of therapy

Safety Issue:

No

Principal Investigator

Chieh Lin, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Molecular Imaging Center and Nuclear Medicine, Chang Gung Memorial Hospital

Authority:

Taiwan: Department of Health

Study ID:

99-2177A

NCT ID:

NCT01691300

Start Date:

May 2011

Completion Date:

December 2015

Related Keywords:

  • Multiple Myeloma
  • C11-acetate PET/CT
  • Multiple myeloma
  • Pretreatment staging
  • Response assessment
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location